Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2014 Future Medicine Ltd. All rights reserved. Colorectal cancer is the third most common cancer in the UK, and represents a significant burden of disease. While there have been few recent advances with traditional therapies, the last few years have seen a rapid expansion of targeted agents, most notably those targeting VEGF, in particular bevacizumab, as treatments providing significant improvements in outcome, particularly in the setting of metastatic disease. However, results in adjuvant therapy have been disappointing and cost remains a major barrier to more widespread use. Many agents are now in varying stages of development as the field continues to expand. The potential benefits of antiangiogenics in colorectal cancer will be improved greatly by the development of methods for stratifying the population and identification of appropriate biomarkers, currently a key area of investigation.

Original publication

DOI

10.2217/EBO.13.635

Type

Book title

Clinical Insights: Antiangiogenesis in Cancer Therapy

Publication Date

01/08/2014

Pages

69 - 89